Report of Foreign Issuer (6-k)
June 25 2019 - 4:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2019
Commission File Number 001-37846
CELLECT BIOTECHNOLOGY LTD.
(Translation of registrant’s name
into English)
23 Hata’as Street
Kfar Saba, Israel 44425
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
This Form 6-K is incorporated by reference
into the registrant’s Registration Statements on Form S-8 (Registration No. 333-214817, 333-220015 and 333-225003) and on
Form F-3 (Registration No. 333-229083, 333-219614 and 333-212432).
On June 25, 2019, Cellect Biotechnology Ltd.
(the “Company”) announced that on July 30, 2019 it will hold at the offices of Doron, Tikotzky, Kantor, Gutman, Nass
& Amit Gross, at B.S.R 4 Tower, 33rd Floor, 7 Metsada Street, Bnei Brak, Israel its annual general meeting to be held at 11:00
a.m. Israel time, or at any adjournment. In connection with the meeting, the Company furnishes the following documents:
1.
|
A copy of the Notice and Proxy Statement with respect to the Company’s Annual General Meeting of Shareholders describing the proposals to be voted upon at the meetings, the procedure for voting in person or by proxy at the meetings and various other details related to the meeting, attached hereto as Exhibit 99.1;
|
2.
|
A form of Proxy Card whereby holders of ordinary shares of the Company may vote at the meeting without attending in person, attached hereto as Exhibit 99.2;
|
3.
|
A form of Voting Instruction Card whereby holders of ADSs of the Company may instruct Bank of New York Mellon to vote at the meeting without attending in person, attached hereto as Exhibit 99.3.
|
Exhibit Index
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Cellect Biotechnology Ltd.
|
|
|
|
|
By:
|
/s/ Eyal Leibovitz
|
|
|
Name: Eyal Leibovitz
|
Date: June 25, 2019
|
|
Title: Chief Financial Officer
|
2
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Oct 2024 to Nov 2024
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Nov 2023 to Nov 2024